Critical Care Management of Chimeric Antigen Receptor T Cell–related Toxicity. Be Aware and Prepared
- 1 July 2019
- journal article
- research article
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 200 (1), 20-23
- https://doi.org/10.1164/rccm.201810-1945ed
Abstract
CAR (chimeric antigen receptor) T cells (CARTs) are genetically engineered T cells that express CARs, with impressive clinical activity in relapsed and refractory hematologic malignancies, primarily acute lymphoblastic leukemia and diffuse large B-cell lymphoma. The most frequent life-threatening adverse events after CART infusion are cytokine release syndrome and CAR-related encephalopathy syndrome, which can occur within hours or days after administration. IL-6 released by macrophages and monocytes plays a major role in the pathogenesis of cytokine release syndrome and CAR-related encephalopathy syndrome, and IL-6 blockade and steroids contribute to fast resolution of symptoms. Critical care management plays an important role in patients receiving CARTs, as up to half of patients might need an admission to the ICU and lifesaving interventions. As new treatment indications and CART constructs enter the clinic, the number of patients requiring ICU admission will rapidly increase, with profound consequences for the use of ICU resources, training requirements, clinical expertise, multidisciplinary collaboration, and hospital organization. Research is also needed to validate at large scale biomarkers that allow doctors to risk-stratify patients for both their risk to develop severe toxicity and their likelihood to respond to therapy.This publication has 20 references indexed in Scilit:
- Tragedy, Perseverance, and Chance — The Story of CAR-T TherapyThe New England Journal of Medicine, 2017
- Chimeric antigen receptor T-cell therapy — assessment and management of toxicitiesNature Reviews Clinical Oncology, 2017
- The Intensive Care Medicine research agenda on critically ill oncology and hematology patientsIntensive Care Medicine, 2017
- Therapeutic T cell engineeringNature, 2017
- Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic LeukemiaCritical Care Medicine, 2017
- Engineered T cells: the promise and challenges of cancer immunotherapyNature Reviews Cancer, 2016
- Critical care of patients with cancerCA: A Cancer Journal for Clinicians, 2016
- Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generationsNature Reviews Drug Discovery, 2016
- Chimeric Antigen Receptor T Cells for Sustained Remissions in LeukemiaThe New England Journal of Medicine, 2014
- Current concepts in the diagnosis and management of cytokine release syndromeBlood, 2014